Slingshot members are tracking this event:

Phase 3 program of filgotinib in Crohn’s disease and the Phase 2/3 program in ulcerative colitis are underway for a start later this year

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 22, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Crohn's Disease, Ulcerative Colitis, Filgotinib